R&D Insights - The CADENCE trial is considered a clear success, but it did not meet the necessary criteria for an FDA submission or regulatory discussion [2] - There were expectations regarding specific numbers or endpoints that would have justified a regulatory conversation, which were not met [2] Commercial Aspects - The discussion indicates a preference to explore R&D before delving into commercial aspects, suggesting a strategic approach to the analysis [1] - The interplay between R&D outcomes and commercial viability is highlighted, emphasizing the importance of successful trials for future regulatory and market opportunities [1]

Market Trend - Gemini releases new Bitcoin commercial [1]